• Advertise
  • About us
  • Terms and Conditions
  • Contact us
Thursday, July 17, 2025
Australian Times News
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia
No Result
View All Result
Australian Times News
No Result
View All Result
Home News

Coronavirus vaccine results are pouring in, and it’s good news for older people

Early results from COVID-19 vaccine trials are starting to emerge, and scientists have received the first reports from three independent studies with optimism because protection against the coronavirus is possible.

The Conversation by The Conversation
20-11-2020 09:17
in News
Coronavirus vaccine results

Coronavirus vaccine results Photo by GR Stocks on Unsplash

Zania Stamataki, University of Birmingham

Early results from COVID-19 vaccine trials are starting to emerge, and scientists have received the first reports from three independent studies with optimism because protection against the coronavirus is possible.

Perfect Wave/Shutterstock

Although we can be relieved that some vaccines work, we still don’t have the details about the parts of the immune system that made the most difference in these trials. The Pfizer/BioNTech team just completed their trial with 95% efficacy, and the Oxford vaccine team has just published the safety and immune response details on their study (it’s more good news for older people). Whether the Oxford vaccine can prevent COVID-19, however, remains to be determined.

So why is this news important? Vaccines are usually first tested in healthy young volunteers to confirm they are safe and to get the first data on efficacy (whether they show any benefit compared with a placebo). Subsequent clinical trials test the vaccine’s efficacy in different groups of people, such as the very young or the very old, and those with other conditions – diabetes or hypertension, say – that could affect their response to the vaccine.

Oxford vaccine results in young and old

Our immune system wanes as we get older, and it becomes more difficult to mount an effective immune response to common germs that younger people can easily expel. It is well-known that older adults are at a much higher risk of severe COVID-19, so it is critical to develop vaccines that can protect this sector of society. Fortunately, booster vaccinations can be used to bolster immunity in older people.

The Oxford vaccine team separated vaccinated people into groups of 18–55 years (160 participants), 56–69 years (160), and 70 years and older (240). Some received the candidate coronavirus vaccine and some a control meningitis vaccine at one or two doses each, to measure if booster vaccination would help. Their new study, published in The Lancet, investigated whether older adults can develop coronavirus-specific immune responses similar to younger adults.

Not only did the older adults develop similar immune responses to younger people, they also tolerated the vaccine better with fewer reports of side-effects, such as fatigue and muscle ache. Neutralising antibodies that block infection and virus-specific T cells are thought to be important for protective immunity, and older adults in the Oxford trial showed evidence of both. Those who received a booster vaccination had even better responses.

AlsoRead...

The Broker who says ‘Yes’ when Banks say NO

The Broker who says ‘Yes’ when Banks say NO

8 July 2025
Leading with Trust: Why Quality still wins in the AI Era

Leading with Trust: Why Quality still wins in the AI Era

5 June 2025

Other coronavirus vaccines in older people

Other studies with vaccine preparations similar to the Oxford group, where the vaccine is delivered by a harmless adenovirus, have reported early results in older people. A single dose adenovirus-based vaccine (CanSino Biological/Beijing Institute of Biotechnology) raised a robust immune response – but less so in those older than 55 years. The two-dose Russian Sputnik V adenovirus vaccine – which also recently reported results in The Lancet – showed consistent responses in under 60s.

Two vaccines using inactivated coronavirus were also able to elicit antibody responses. The Wuhan Institute Biological Products/SinoPharm study showed that volunteers under 59-years-old generated neutralising antibodies, and the Beijing Institute Biological products/SinoPharm study measured robust antibodies but showed lower responses in the over 60s.

A different vaccine approach involves the use of mRNA, messenger molecules that enter our cells and kick off the production of coronavirus proteins to stimulate our immune system. Two mRNA-based vaccines with two-dose protocols were tested under-55s and over-65s with positive results. The Pfizer/BioNTech vaccine was the first concluded trial with 95% final efficacy, and they estimated the efficacy for over 65s at an impressive 94%.

Moderna also has released exciting interim efficacy data and previously reported potent neutralising responses in both under 55s and those over 56.

Early results from ongoing trials show that we are able to design vaccines that elicit potent coronavirus responses in people over 60. Vaccine efficacy will vary with different vaccine preparations, and we need to choose carefully which formulations will work best in older people, which doses are most effective and when to administer booster vaccinations to achieve the best results.

It has been less than a year since the new coronavirus jumped to humans, and we are entering the privileged position of being able to choose between different vaccines.

Zania Stamataki, Senior Lecturer in Viral Immunology, University of Birmingham

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Tags: SB001
DMCA.com Protection Status

SUBSCRIBE to our NEWSLETTER

[mc4wp_form id=”2384248″]

Don't Miss

The Dating Wealth Gap Is Getting Wider: What You Should Know

by Fazila Olla-Logday
11 July 2025
Source: Pixabay
Lifestyle

The divide between wealth and romance is growing. As income inequality widens, financial status is playing a bigger role in...

Read more

The Broker who says ‘Yes’ when Banks say NO

by Pauline Torongo
8 July 2025
The Broker who says ‘Yes’ when Banks say NO
Business & Finance

When faced with constant loan rejection or last-minute withdrawals of support, Trelos Finance stands out as a solution.

Read more

Common Mistakes When Buying a Telescope — And How to Avoid Them

by Fazila Olla-Logday
1 July 2025
Common Mistakes When Buying a Telescope
Technology

You’ve spent hours scrolling through telescope specs online, dazzled by features and grand promises. The excitement builds—until your newly arrived...

Read more

From Portugal to Bali: Where Aussies Should Go for Your Next Coastal Holiday

by Fazila Olla-Logday
20 June 2025
Source: Flickr
Travel

Aussies, here is a guide to where you should go for your next coastal holiday.

Read more

Leading with Trust: Why Quality still wins in the AI Era

by Pauline Torongo
5 June 2025
Leading with Trust: Why Quality still wins in the AI Era
Business & Finance

If you're leading a software team today, you've likely noticed the shift: faster feature rollouts, routine automation, and AI taking...

Read more

How to Save on Airport Parking: Budget Tips Every Traveller Should Know

by Fazila Olla-Logday
3 June 2025
How to Save on Airport Parking
Travel

Saving money on airport parking can be a challenge,but here are some budget friendly tips to help you navigate.

Read more

Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin

by Pauline Torongo
28 May 2025
Why Australian Investors are Betting on the Aviation Maverick Louis Belanger-Martin
Business & Finance

Bélanger-Martin’s ambitions stretch beyond redefining inflight comfort—they’re rooted in resurrecting the romance of supersonic travel with a modern twist.

Read more
Load More

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status

  • About us
  • Write for Us
  • Advertise
  • Contact us
  • T&Cs, Privacy and GDPR
No Result
View All Result
  • News
    • Weather
    • Sport
    • Technology
    • Business & Finance
      • Currency Zone
    • Lotto Results
      • The Lott
  • Lifestyle
    • Entertainment
    • Horoscopes
    • Health & Wellness
    • Recipes
  • Travel
  • Expat Life
  • Move to Australia

Copyright © Blue Sky Publications Ltd. All Rights Reserved.
australiantimes.co.uk is a division of Blue Sky Publications Ltd. Reproduction without permission prohibited. DMCA.com Protection Status